# LifePearl-Doxo Pharmacokinetic (PK) Study

> **NCT02548780** · NA · COMPLETED · sponsor: **Terumo Europe N.V.** · enrollment: 15 (actual)

## Conditions studied

- HCC
- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** Chemoembolization
- **OTHER:** Pharmacokinetics

## Key facts

- **NCT ID:** NCT02548780
- **Lead sponsor:** Terumo Europe N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2018-10
- **Final completion:** 2019-10-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02548780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02548780, "LifePearl-Doxo Pharmacokinetic (PK) Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02548780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*